In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: National uniformity legislation

This article was originally published in The Tan Sheet

Executive Summary

National uniformity legislation: Rep. Richard Burr's (R-N.C.) HR 1411, introduced April 23, includes national uniformity language that prohibits states from enacting any requirements inconsistent with the federal Public Health Service Act or the Fair Packaging & Labeling Act, including any "notification requirement for a drug package thereof." The "Drug & Biological Products Modernization Act," which remains virtually unchanged from a July discussion draft, updates Burr's HR 3199 introduced in the 104th Congress. Pushing for national uniformity in OTC drug regulation remains one of the Nonprescription Drug Manufacturers Association's top legislative priorities...





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts